一项评估HSK21542用于骨科手术后疼痛治疗患者的疗效和安全性的2期临床试验
一项多中心、随机、双盲、安慰剂/活性对照的II期临床研究,旨在评估HSK21542注射液用于骨科手术后疼痛治疗的疗效和安全性
This is a multi-center, randomized, double-blind, placebo/active-controlled study. 160 subjects undergoing orthopedic surgery under general anesthesia are planned to be enrolled and randomized into the HSK21542 group, morphine group, and placebo group.
研究概览
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
Chongqing、中国
- The Second Affiliated Hospital of Chongqing Medical University
-
Shanghai、中国
- Huashan Hospital, Fudan University
-
Shenzhen、中国
- Shenzhen Second People's Hospital
-
-
Anhui
-
Hefei、Anhui、中国
- The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
-
-
Guangdong
-
Guangzhou、Guangdong、中国
- The Third Affiliated Hospital, Southern Medical University
-
-
Guangxi
-
Liuzhou、Guangxi、中国
- Liuzhou People's Hospital
-
-
Hebei
-
Cangzhou、Hebei、中国
- Hebei Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine
-
Shijiazhuang、Hebei、中国
- The Third Hospital of Hebei Medical University
-
Shijiazhuang、Hebei、中国
- The First Hospital of Hebei Medical University
-
-
Heilongjiang
-
Harbin、Heilongjiang、中国
- The Fourth Affiliated Hospital of Harbin Medical University
-
Harbin、Heilongjiang、中国
- The Second Affiliated Hospital of Harbin Medical University
-
-
Hubei
-
Yichang、Hubei、中国
- Yichang Central People's Hospital (Wujia Campus)
-
Yichang、Hubei、中国
- Yichang Central People's Hospital (Xiling Campus)
-
-
Hunan
-
Changsha、Hunan、中国
- The Second Xiangya Hospital of Central South University
-
Changsha、Hunan、中国
- Xiangya Hospital of Central South University
-
-
Jiangsu
-
Huaian、Jiangsu、中国
- Huai'an Second People's Hospital
-
Nanjing、Jiangsu、中国
- Nanjing First Hospital
-
Nanjing、Jiangsu、中国
- Zhongda Hospital, Southeast University
-
Wuxi、Jiangsu、中国
- Wuxi People's Hospital
-
-
Jiangxi
-
Ganzhou、Jiangxi、中国
- Ganzhou People's Hospital
-
-
Shandong
-
Jinan、Shandong、中国
- The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)
-
-
Sichuan
-
Mianyang、Sichuan、中国
- Mianyang Central Hospital
-
Mianyang、Sichuan、中国
- Mianyang Orthopedic Hospital
-
Suining、Sichuan、中国
- Suining Central Hospital
-
-
Zhejiang
-
Huzhou、Zhejiang、中国
- Huzhou Central Hospital
-
Jinhua、Zhejiang、中国
- Jinhua Central Hospital
-
Wenzhou、Zhejiang、中国
- The First Affiliated Hospital of Wenzhou Medical University
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- 18 years old ≤ age ≤74 years old, regardless of gender;
- 18 kg/m2≤BMI≤32 kg/m2, meet the weight range specified in the protocol;
- American Society of Anesthesiologists (ASA) grade 1-3;
- Accept hip replacement under general anesthesia;
- Within 4 hours after the end of surgery, NRS≥4 in the resting state at any time;
- Fully understand and voluntarily participate this trial, and sign the informed consent form;
Exclusion Criteria:
- Patients with allergy to opioids or any component of the trial drug;
- Patients with a history of severe cardiovascular and cerebrovascular diseases, ,and psychiatric disorders;
- Last use of opioid or non-opioid analgesics less than 5 half-lives or the duration of drug efficacy prior to randomization; use of drugs with unclear half-lives that may affect analgesic efficacy within 7 days prior to randomization, or last use of drugs affecting analgesic efficacy less than 5 half-lives prior to randomization, as well as Chinese herbal medicines or proprietary Chinese medicines deemed by the investigator as potentially impacting the evaluation of efficacy and safety;
- Continuous use of opioid analgesics for more than 7 days for any reason within 30 days prior to screening;
- Laboratory test results during the screening period meeting any of the following criteria: 1) Significantly abnormal hematology results; 2) Significantly abnormal prothrombin time test results; 3) Significantly abnormal liver or kidney function; 4) Significantly abnormal fasting blood glucose;
- Positive test results during the screening period for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCVAb), syphilis antibody, or human immunodeficiency virus (HIV) antibody;
- A history of drug, drug, and/or alcohol abuse
- Participate in any clinical trail within 30 days;
- Pregnant or lactating female subjects;
- Subjects of childbearing potential who are unwilling to use contraception throughout the study period or plan to become pregnant within 3 months after the study.
- Subjects with any other factor considered by the investigator to be ineligible for participation in the trial.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:HSK21542 dose level 1
Patients administrated with HSK21542 dose level 1 |
Patients administrated with HSK21542 dose level 1 |
|
实验性的:HSK21542 dose level 2
Patients administrated with HSK21542 dose level 2 |
Patients administrated with HSK21542 dose level 2 |
|
安慰剂比较:Placebo control
Patients administrated with placebo |
Patients administrated with placebo |
|
有源比较器:Actice control
Patients administrated with morphine |
Patients administrated with morphine |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Sum of Pain Intensity Differences (SPID)
大体时间:48 hours
|
Sum of Pain Intensity Differences (SPID) of each group |
48 hours
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Sum of Pain Intensity Differences (SPID) in other time frame
大体时间:0-8 hours, 0-24 hours, 24-48 hours
|
Sum of Pain Intensity Differences (SPID) in other time frame |
0-8 hours, 0-24 hours, 24-48 hours
|
|
Number of times rescue analgesic medications were administered.
大体时间:48 hours
|
Number of times rescue analgesic medications were administered. |
48 hours
|
|
Total morphine consumption
大体时间:48 hours
|
Total morphine consumption of each group |
48 hours
|
|
Proportion of subjects experiencing nausea and/or vomit
大体时间:48 hours
|
Proportion of subjects experiencing nausea and/or vomit of each group |
48 hours
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.